These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 1791971

  • 21. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.
    Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH.
    Brain Res; 1990 Apr 16; 513(2):320-4. PubMed ID: 2350702
    [Abstract] [Full Text] [Related]

  • 22. Nucleoside diphosphate kinase associated with rat pancreatic membranes regulates CCK receptor affinity.
    Blevins GT, van de Westerlo EM, Williams JA.
    Am J Physiol; 1994 Nov 16; 267(5 Pt 1):G866-74. PubMed ID: 7977749
    [Abstract] [Full Text] [Related]

  • 23. Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment.
    He L, Di Monte DA, Langston JW, Quik M.
    Neuroscience; 2000 Nov 16; 99(4):697-704. PubMed ID: 10974432
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT, Christoffersen CL, Serpa KA, Razmpour A.
    Synapse; 1993 Feb 16; 13(2):117-22. PubMed ID: 8446920
    [Abstract] [Full Text] [Related]

  • 25. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists.
    Hill DR, Campbell NJ, Shaw TM, Woodruff GN.
    J Neurosci; 1987 Sep 16; 7(9):2967-76. PubMed ID: 3625281
    [Abstract] [Full Text] [Related]

  • 26. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW, Holladay MW, Barrett RW, Wolfram CA, Miller TR, Witte D, Kerwin JF, Wagenaar F, Nadzan AM.
    Mol Pharmacol; 1989 Dec 16; 36(6):881-6. PubMed ID: 2601685
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Densities of dopamine D2 receptors are reduced in CNS regions of alcohol-preferring P rats.
    McBride WJ, Chernet E, Dyr W, Lumeng L, Li TK.
    Alcohol; 1993 Dec 16; 10(5):387-90. PubMed ID: 8216885
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effects of chronic clozapine and haloperidol on midbrain dopamine neurons.
    Minabe Y, Ashby CR, Wang RY.
    Brain Res; 1991 May 17; 549(1):151-4. PubMed ID: 1893248
    [Abstract] [Full Text] [Related]

  • 33. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
    Knapp RJ, Vaughn LK, Fang SN, Bogert CL, Yamamura MS, Hruby VJ, Yamamura HI.
    J Pharmacol Exp Ther; 1990 Dec 17; 255(3):1278-86. PubMed ID: 2262906
    [Abstract] [Full Text] [Related]

  • 34. Characterization of cholecystokinin receptors on the human gallbladder.
    Tokunaga Y, Cox KL, Coleman R, Concepcion W, Nakazato P, Esquivel CO.
    Surgery; 1993 Feb 17; 113(2):155-62. PubMed ID: 7679224
    [Abstract] [Full Text] [Related]

  • 35. 125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
    Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T.
    Exp Neurol; 2000 May 17; 163(1):191-9. PubMed ID: 10785458
    [Abstract] [Full Text] [Related]

  • 36. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
    Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU.
    J Neurochem; 1992 Aug 17; 59(2):733-9. PubMed ID: 1629743
    [Abstract] [Full Text] [Related]

  • 37. Characteristics of 125I-Bolton-Hunter labelled cholecystokinin binding in human brain.
    Cross AJ, Slater P, Skan W.
    Neuropeptides; 1988 Aug 17; 11(2):73-6. PubMed ID: 3368039
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas.
    Marzatico F, Café C, Taborelli M, Benzi G.
    Neurochem Res; 1993 Oct 17; 18(10):1101-6. PubMed ID: 8255359
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.